Skip to Content

Wilate Approval History

  • FDA approved: Yes (First approved December 4th, 2009)
  • Brand name: Wilate
  • Generic name: von Willebrand Factor/Coagulation Factor VIII Complex (Human)
  • Dosage form: Injection
  • Company: Octapharma USA
  • Treatment for: von Willebrand's Disease

Wilate is a von Willebrand Factor/Coagulation Factor VIII Complex (Human) indicated for the treatment of spontaneous and trauma-induced bleeding episodes in patients with severe von Willebrand disease (VWD).

Development History and FDA Approval Process for Wilate

Dec  8, 2009Approval Octapharma USA Announces FDA Approval of Wilate - the First Replacement Therapy Developed Specifically for von Willebrand Disease

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.